Theres only one category of peptide medications with strong clinical evidence for fat loss: GLP-1 receptor agonists (like semaglutide or tirzepatide)
In published research it has been investigated for its effects on tissue repair, angiogenesis, gastrointestinal mucosal protection and anti-inflammatory signalling in animal and cell-culture models
GH and IGF-1 operate via generalized anabolic stimulation and mitogenesis, whereas BPC-157 appears to favor modulation of the tissue microenvironment (local angiogenesis, controlled inflammation, endothelial stabilization)
This property makes it suitable for research environments where maintaining solution quality throughout multiple withdrawals is important
When you see BPC-157 10mg referenced on the site, it is accompanied by disclaimers that it is not for human consumption, injection, or any type of clinical use, reinforcing that its role is limited to the lab bench and controlled experimental environments